List of Breast Cancer, Metastatic Medications (43 Compared) - Drugs.com - iressa for metastatic breast cancer

Category

iressa for metastatic breast cancer - Gefitinib - National Cancer Institute


May 19, 2008 · Iressa Shows Promise For Treatment Of Metastatic Breast Cancer When Combined With Hormonal Therapy Date: May 19, 2008 Source: University of Texas M. D. Anderson Cancer Center. Jun 13, 2017 · Metastatic, or stage 4, breast cancer means the cancer has spread to other parts of the body. Find out about prognosis and life expectancy at this stage.Author: Robin Madell.

Iressa (gefitinib) is a cancer medication that interferes with the growth and spread of cancer cells in the body. Iressa is used to treat non-small cell lung cancer.. Iressa is sometimes used to treat cancer that has spread to other parts of the body.9.6/10. Being told you have metastatic (stage IV) breast cancer is a lot to take in. It means your cancer has spread to other parts of your body. Although there is no cure, your doctor has ways to slow.

Although metastatic breast cancer has spread to another part of the body, it’s still breast cancer and treated as breast cancer. For example, breast cancer that has spread to the bones is still breast cancer (not bone cancer). It may also be called metastatic breast cancer in the bones or bone metastases. FDA label information for this drug is available at DailyMed. Use in Cancer. Gefitinib is approved to treat: Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFR gene mutations.; Gefitinib is also being studied in the treatment of other types of cancer.

About Breast Cancer, Metastatic: Metastatic breast cancer (Stage IV breast cancer) is an advanced form of breast cancer that occurs when breast cancer cells spread from the breast into surrounding tissue and distant organs. Drugs Used to Treat Breast Cancer, Metastatic. Jul 13, 2015 · Monday, 13 July 2015. AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved IRESSA ® (gefitinib) as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA .

Role of Epidermal Growth Factor Receptor in Breast Cancer. Four of the 59 evaluable patients with metastatic breast cancer positive for both EGFR and HER2, Dennison SK, Jacobs SA, Wilson JW, et al. A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.Cited by: 327.